Master Class On Demand Learning

The goal of this course is to assist oncologists with assessing and improving their skills in the diagnosis, treatment, and management of a wide range of cancers.

Recordings from the innovative, live two-day curriculum provide a comprehensive update on oncologic clinical practice, including current best practices and guidelines, emerging clinical evidence, and recent expert opinion. Learners benefit from the same highly interactive presentations followed by lively discussion sessions, including both Q&A and panel discussions, however, may participate at their leisure. On demand access will be available November 11, 2022 and participation and credit claiming will be available for one year.

In support of improving patient care, this activity has been planned and implemented by CME Outfitters, LLC and Dana-Farber Cancer Institute. CME Outfitters, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
CME Outfitters, LLC, designates this live activity for a maximum of 16.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Master Class On Demand curriculum is intended to educate practicing community medical oncologists across the US.

MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learners must provide their Date of Birth (MM/DD) and ABIM ID# to Dana-Farber Cancer Institute to claim points for this activity.

Dana-Farber Cancer Institute gratefully acknowledges organizations for providing educational grants or financial support for this activity.

• Astellas Pharma (Gastrointestinal Cancers and Genitourinary Cancers Tracks)
• AstraZeneca Pharmaceuticals (Women’s Cancers, Genitourinary Cancers, Malignant and Non-Malignant Hematology Tracks)
• Bayer HealthCare (Sarcoma Track)
• Daiichi Sankyo, Inc. (Women’s Cancers and Lung, Head, and Neck and Thyroid Cancers Tracks)
• Exelixis, Inc. (Lung, Head, and Neck and Thyroid Cancers and Genitourinary Cancers Tracks)
• GlaxoSmithKline (All Tracks)
• Merck Sharp & Dohme LLC (Women’s Cancers Track)
• Novartis Pharmaceuticals Corporation (All Tracks)
• Pfizer Inc. (All Tracks)
• Taiho Oncology, Inc. (All Tracks)

Registration for the On Demand course is $250 and includes access to pdfs of the faculty presentations via the website. An electronic syllabus is also available to download.

Information on how to access the On Demand activity coming soon.